This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the clinical landscape of Thyroid Eye Disease (TED) with an updated look at Tepezza. Also reviewing the potential of Viridian Therapeutics VRDN-001, an anti-IGF-1R antibody for patients with active TED.

Ticker(s): VRDN, HZNP

Who's the expert?

Institution: Diabetes and Metabolism Specialists 

  • Endocrinologist at Diabetes and Metabolism Specialists in San Antonio, Texas
  • Diabetes and Metabolism physician who manages over 500 type 1 diabetes patients, 300 of which are on insulin pumps
  • Research interest in inititation, titration, and switching of basal insulins 

Interview Goal
Interview a clinician with experience treating TED patients with Tepezza and to discuss the phase 1/2 data of Viridian's VRDN-001 antibody.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.